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Abstract 
The aim of this retrospective study was to evaluate the characteristics of increased bone marrow uptake of 18F‑FDG 
in patients with leukemia who underwent whole‑body 18F‑FDG PET/CT. The 18F‑FDG PET/CT images of 9 patients 
with histologically proven leukemia were reviewed. The accumulation of 18F‑FDG in the bone marrow was evalu‑
ated, and was compared with histological subtype, clinical course, and hematological findings. Nine patients (4 males, 
5 females; age range, 5–58 years) had increased bone marrow uptake of 18F‑FDG, including 6 patients with acute 
lymphoblastic leukemia, 1 with acute myeloid leukemia, 1 with chronic myeloid leukemia, and 1 with mature B cell 
neoplasm. Bone marrow uptake was generally diffuse but focal or inhomogeneous uptake was common, especially 
in the upper and lower extremities. Patients with increased bone marrow uptake of 18F‑FDG commonly complained 
of fever and bone pain. No correlations between 18F‑FDG uptake and peripheral blood findings were observed. 
Patients with leukemia may have increased bone marrow uptake of 18F‑FDG on PET/CT, possibly reflecting leukemic 
cell activity. Leukemia can be included in the differential diagnosis when increased bone marrow uptake of 18F‑FDG 
is observed.
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Background
Leukemia is a hematological malignancy characterized 
by malignant cells that exist mainly in the bone marrow 
(BM) and peripheral blood. An estimated 48,610 new 
cases of leukemia are diagnosed in the US every year, 
resulting in 23,720 deaths. Leukemia is the leading cause 
of cancer-related deaths in males aged <40 years, and the 
second leading cause of cancer-related deaths in females 
aged <20 years (Siegel et al. 2013).
Although 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) or 18F-FDG PET/com-
puted tomography (CT) is widely used for the diagno-
sis, staging, and response assessment of various types of 
malignancy, it is not routinely used in patients with leu-
kemia, because leukemia typically does not present with 
a solid tumor, and because clinical use of this investiga-
tion in patients with leukemia has only been described 
in few case reports (Takalkar et al. 2004; Rao et al. 2009; 
Takahashi et  al. 2011; Su et  al. 2013; Arslan et  al. 2014; 
Parida et al. 2015). We previously reported a case of acute 
lymphoblastic leukemia associated with diffuse homoge-
neous BM uptake of 18F-FDG (Su et  al. 2013), indicat-
ing that some patients with leukemia who have tumor 
cells in the BM aspirate also have increased BM uptake 
of 18F-FDG on PET/CT. Therefore, we hypothesized that 
increased BM uptake of 18F-FDG may be a characteristic 
finding in patients with leukemia.
Increased BM uptake of 18F-FDG is sometimes 
observed after chemotherapy, after administration of 
granulocyte colony-stimulating factor, in patients with 
malignant lymphoma, and in patients with multiple 
bone metastases. This increased uptake is considered 
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to be caused by increased numbers or increased activity 
of normal hematopoietic cells or tumor cells in the BM. 
However, the frequency of increased BM uptake of 18F-
FDG in patients with leukemia, and associations between 
uptake characteristics and laboratory findings, are cur-
rently unknown.
The purpose of this study was to evaluate the imaging 




Patients were retrospectively identified from our clinical 
PET/CT database, in which all PET/CT studies in our insti-
tution have been consecutively registered. The diagnosis of 
each patient was confirmed by his or her electronic medi-
cal record after PET/CT study, because PET/CT is often 
performed before invasive procedures such as biopsy or 
surgery. Between December 2010 and November 2013, 50 
18F-FDG PET/CT scans were performed at our institute in 
33 patients with histologically proven leukemia. The exclu-
sion criteria were as follows: (1) recent administration of 
chemotherapy within 30 days before PET/CT (n = 15), (2) 
recent stem-cell transplantation within 1 year before PET/
CT (n = 3), (3) co-existing malignant or active inflamma-
tory lesions (n  =  2), (4) lymphoma type presentation of 
adult T-cell leukemia/lymphoma (n = 2), (5) chronic lym-
phocytic leukemia/small lymphocytic lymphoma (n =  1), 
(6) recent administration of granulocyte stimulation-factor 
(n = 0), and (7) insufficient follow-up data (n = 1). All but 
the last criteria are associated with increased bone marrow 
uptake (Su et al. 2013). After the exclusion of 24 patients, 
the imaging findings of the remaining 9 patients were 
analyzed (4 males, 5 females; age range, 5–58 years). 18F-
FDG PET/CT was performed for pre-therapeutic staging 
in 5 patients (to evaluate potential extramedullary disease 
or an inflammatory process before stem cell transplanta-
tion or chemotherapy), for re-staging in 2 patients (relapse 
after a stable status lasting for at least 3 years), and to inves-
tigate prolonged unexplained pyrexia in 2 patients who 
were subsequently diagnosed with leukemia. Repeat PET/
CT for response assessment after leukemia treatment was 
performed in 4 of the 9 patients and the images obtained 
before and after treatment were compared.
This retrospective study was approved by the ethics 
committee of our institute, and written informed consent 
for data access was obtained from all patients. For those 
younger than 20 years of age, written informed consent 
was obtained from both the parents and the patients.
18F‑FDG PET/CT scanning
18F-FDG PET/CT was performed using a combined 
PET/CT scanner (Discovery ST Elite; GE Healthcare 
Ltd., Waukecha, WI USA). Patients fasted for at least 4 h 
before intravenous administration of 3.7  MBq/kg body 
weight of 18F-FDG. The 18F-FDG dose for children was 
determined according to the revised European Associa-
tion of Nuclear Medicine pediatric dosage card. Approxi-
mately 1 h (range 46–96 min, mean 64 ±  15 min) after 
the administration of 18F-FDG, whole-body PET was 
performed, with 2–3 min per bed position. The scanning 
range was from the upper thigh to the skull in 3 patients, 
and was extended to include the lower extremities in the 
remaining 6 patients because they had increased uptake 
in the femurs or pain in the legs. The CT data were used 
for attenuation correction, and images were recon-
structed using the 3-dimensional iterative reconstruction 
algorithm VUE Point Plus.
18F‑FDG PET/CT image analysis
18F-FDG PET/CT images were visually interpreted by 
2 board-certified nuclear medicine physicians (M.K.A., 
with 4  years of experience interpreting PET; and Y.N., 
with 18  years of experience interpreting PET) and the 
results were recorded by consensus. Increased BM 
uptake of 18F-FDG was defined as uptake that was 
greater than in the liver. This method is used to evalu-
ate BM uptake in lymphoma (Carr et al. 1998, Cerci et al. 
2014). The distribution and pattern of BM uptake were 
classified region by region as (a) diffuse and homogene-
ous or (b) focal or inhomogeneous. The most intensive 
foci within the BM were identified using a 3D-volume 
viewer (Advantage Workstation 4.4, GE, Little Chalfont, 
UK). The maximum standardized uptake value (SUVmax) 
of the most intensive focus was measured manually. Care 
was taken to avoid organs with physiological uptake. The 
SUVmax of a region of interest located in the right lobe of 
the liver served as reference. Associated findings, such as 
splenomegaly, lymph node swelling, and extramedullary 
lesions, were also evaluated. The SUVmax of the BM was 
compared with the patient’s hematological findings.
Results
The clinical characteristics, PET findings, and laboratory 
data of the patients are shown in Table 1. Increased BM 
FDG uptake was observed in all 9 patients; including a 
diffuse and homogeneous pattern throughout the body 
in 1 patient and the coexistence of diffuse/homogeneous 
and focal/inhomogeneous patterns in 8 patients.
The BM SUVmax of the 9 patients ranged from 4.5 to 
14.0 (mean: 6.6 ±  2.8) whereas the SUVmax of the liver 
ranged from 1.3 to 4.2 (mean: 2.5 ±  0.8). All 9 patients 
underwent BM biopsy within 8  days (mean 4.3  days) 
of PET/CT. The findings were confirmed histopatho-
logically in 8 patients. In the remaining patient (Patient 
9), the results were inconclusive despite repeat BM 
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examinations; instead, leukemia was confirmed based on 
the presence of leukemic cells in the peripheral blood. 
The final diagnosis was acute lymphoblastic leukemia in 
6 patients, acute myeloid leukemia in 1 patient, chronic 
myeloid leukemia in 1 patient, and mature B-cell neo-
plasm in 1 patient.
The distribution and pattern of BM uptake of 18F-FDG 
are shown in Table  2. The BM biopsy site confirmed to 
contain leukemic cells and the site where the BM SUVmax 
was recorded are also indicated in Table  2. The pattern 
of increased 18F-FDG uptake was generally diffuse, with 
frequent focal or inhomogeneous uptake, especially in 
the upper and lower extremities (Fig. 1). 
All 9 patients complained of fever or bone pain. In the 
2 patients with fever of unknown origin, the hypermeta-
bolic activity of the BM was useful in the determination 
of the optimal biopsy site, and resulted in the accurate 
diagnosis of leukemia.
After PET/CT and obtaining the final diagnosis, all 
patients received chemotherapy, followed by BM trans-
plantation in 4 patients (Patients 1, 3, 6, and 7). Four 
patients (Patients 2, 3, 4, and 5) underwent repeat PET/
CT after treatment. A decrease in the BM uptake of 18F-
FDG following treatment was determined in these four 
patients based on comparisons with the pre-treatment 
PET/CT images. In addition, repeat BM examinations 
confirmed the decrease in number of leukemic cells. The 
outcome of the other patients varied, as shown in Table 1.
18F-FDG uptake was increased in the spleen of 5 
patients (Fig.  2). None of the patients had increased 
uptake in the lymph nodes or in extramedullary sites. 
No associations were observed in this small population 
between SUVmax of the BM and the patients’ hematologi-
cal data such as the white blood cell count, hemoglobin 
level, hematocrit, platelet count, C-reactive protein level, 
and lactate dehydrogenase level.
Discussion
In this study, all 9 patients with leukemia had increased 
BM uptake of 18F-FDG on PET/CT. In 8 of them, leu-
kemic cells in the BM were confirmed by BM exami-
nation performed at the same time. In the 4 patients 
Table 1 Clinical characteristics of patients with leukemia
WBC white blood cell count, Hb hemoglobin, PLT platelet count, LDH lactate dehydrogenase, CRP C-reactive protein, BM bone marrow, B-ALL B-cell acute 
lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myeloid leukemia, CBT cord blood stem cell transplantation, CTX chemotherapy, BMT bone 
marrow transplantation, CR complete remission, PR partial remission
Patient 1 2 3 4 5 6 7 8 9
Age (years) 35 5 24 10 6 58 24 16 8
Sex F F M F F F M M M
Chief complaints
 Fever + + − + + + + + +
 Bone pain + + + + + + + − +
Laboratory data
 WBC (/µL) 2700 6900 4400 18,100 11,900 1100 9100 175,100 11,100
  Leukemic cells (%) 0 0 0 64 11.5 3 21.5 4.5 12
 Hb (g/dL) 10.3 11.0 12.4 12.1 11.8 8.6 14.3 10.5 12.5
 PLT (×103/μL) 340 300 48 22 115 58 184 59 63
 LDH (IU/L) 190 183 262 955 367 300 489 972 11,021
 CRP (mg/dL) 5.1 4.2 7.3 2.4 11.9 8.3 3.2 0.6 0.8
FDG‑PET
 Abnormal BM uptake + + + + + + + + +
 SUVmax of BM 6.8 4.5 5.6 6.0 6.1 6.1 14.0 4.8 5.9
 SUVmax of liver 2.4 1.4 4.2 2.4 2.5 2.6 2.7 2.7 1.3
 Lymph node swelling − − − − − − − − −
 Splenomegaly − − − + + − + + +
 Increased uptake in spleen − − − + + + + − +
 Extramedullary lesion − − − − − − − − −
Diagnosis B‑ALL B‑ALL B‑ALL B‑ALL B‑ALL AML B‑ALL CML mature B
Time to diagnosis (months) 20 4 6 0 1 0 0 0 1
Treatment CBT CTX CBT CTX CTX BMT CBT CTX CTX
Outcome CR CR PR PR PR PR PR Dead –
Follow‑up (months) 33 22 21 19 18 17 14 1 3
Page 4 of 6Arimoto et al. SpringerPlus  (2015) 4:521 
who underwent repeat 18F-FDG PET/CT after chemo-
therapy, the decrease in the abnormal uptake was con-
sistent with the decrease in the number of leukemic 
cells determined on repeat BM examination. These 
results suggest that an increase in BM uptake reflects 
an increase in either the number or the metabolic 
activity of leukemic cells in the BM, although normal 
hematopoietic cells may also demonstrate hyperactiv-
ity. Carr et al. (1998) reported that visual interpretation 
of BM uptake of 18F-FDG on whole-body PET could 
accurately identify BM infiltration by lymphoma. Some 
types of leukemia and lymphoma are histologically and 
immunophenotypically similar, and represent different 
clinical presentations of the same neoplasm (Sato et al. 
2008; Vardiman et  al. 2009). It is therefore reasonable 
that leukemic cells may cause increased BM uptake of 
18F-FDG.
In our patients, increased BM uptake of 18F-FDG was 
generally observed in the vertebrae, pelvis, sternum, ribs, 
and extremities. Although the high BM uptake is not 
specific for leukemic infiltration since reactive changes 
caused by anemia or use of colony stimulating factors 
may show similar findings, the distribution of increased 
uptake was greater than the distribution of physiological 
uptake in red BM, which might be characteristic of, but 
not limited to leukemia.
Table 2 Patterns of Abnormal Bone Marrow Uptake of 18F‑FDG
C cervical vertebra, T thoracic vertebra, L lumbar vertebra, D diffuse and homogeneous increased uptake, F focal or inhomogeneous increased uptake, – no increased 
uptake, NA not available (out of scan)
a The bone marrow biopsy site was confirmed to contain leukemic cells
b The most intensive foci of each patient, in which SUVmax was measured
Patient Skull C T L Pelvis Sternum Rib Humerus Radius/ulna Femur Tibia/fibula
1 – D D D Da D D D D Db D
2 – – – – – D – D D F Da,b
3 – – – D Da – – F NA Fb F
4 – D D D Da D – Fb – D D
5 – D D D Da D – F D Fb D
6 – D D Db Da D D F – F –
7 – D D D Da,b D D F – F NA
8 – D D D Da,b D – D – F F
9 D D D D D D D D D Db F
Fig. 1 18F‑FDG PET/CT images of a 24‑year‑old man with B‑cell acute lymphoblastic leukemia (Patient 3). Maximum‑intensity projection PET image 
extended to the legs (a, b) and sagittal PET/CT images (c), showing inhomogeneous bone marrow uptake. There are areas of decreased 18F‑FDG 
uptake in the legs, especially in the proximal right tibia (b, arrow)
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Some of the patients in this study had focal or inho-
mogeneous BM uptake of 18F-FDG, especially in the 
extremities. This may reflect either the localization of 
leukemic cells in the BM or focal areas with a decrease 
in the number or activity of leukemic cells because of BM 
necrosis, which is caused by hypoxemia after the failure 
of the microcirculation. In patients with leukemia, the 
leukemic population may outgrow its blood supply and 
impinge upon vascular structures (Janssens et  al. 2000). 
BM necrosis at sites without increased FDG uptake was 
not confirmed histopathologically in our patients because 
of clinical and ethical considerations.
Use of PET to detect focal bone localization of leukemia 
has been reported in several cases, especially in patients 
with relapse (Endo et al. 2004; von Falk et al. 2009; Ciar-
allo et al. 2011). In 1 patient in this study (Patient 2), BM 
aspiration from an area of increased uptake in the tibia 
resulted in definitive diagnosis of leukemia. 18F-FDG 
PET/CT may be useful for guiding the site of BM aspira-
tion in such cases.
18F-FDG PET/CT has also been used in response 
assessment after leukemia treatment (Nakajo et al. 2007). 
In our study, the decrease in BM uptake after therapy 
coincided with a decrease in the number of leukemic cells 
in the BM in 4 patients. Therefore, 18F-FDG PET/CT 
performed after treatment may be useful for non-invasive 
response assessment in patients with increased pre-
treatment BM uptake of 18F-FDG. However, whether 
a reactive increase in the BM uptake of 18F-FDG after 
treatment will adversely affect the diagnostic utility of 
this approach remains to be determined.
18F-FDG PET/CT may enable early diagnosis of leu-
kemia in patients without leukemic cells in the periph-
eral blood. It is likely to be especially useful in the small 
proportion of patients with relatively normal blood cell 
counts at the initial presentation (Kato et  al. 2011). If 
leukemic cells exist only in the BM, BM aspiration or 
biopsy is necessary to confirm the diagnosis. As bone 
pain and fever are non-specific symptoms, diagno-
sis may be delayed in patients presenting with these 
symptoms (van del Have et al. 2012; Parida et al. 2015). 
In this study, the time from the detection of the first 
symptoms to the diagnosis was longer in the 3 patients 
without than in the 6 patients with leukemic cells in 
the peripheral blood. In such cases, imaging modalities 
such as magnetic resonance (Bartakke et al. 2007; Kato 
et  al. 2011) and PET/CT (Ennishi et  al. 2009; Su et  al. 
2013; Arslan et  al. 2014) may enable the earlier detec-
tion of BM abnormalities and thus an earlier initiation 
of treatment (Derlin et al. 2011). In fact, PET/CT is of 
greater utility than MRI because it can easily scan the 
whole body.
Fig. 2 18F‑FDG PET/CT images of a 24‑year‑old man with B‑cell acute lymphoblastic leukemia (Patient 7). Maximum‑intensity projection PET image 
(a) and sagittal PET/CT images (b), showing diffuse homogeneous bone marrow uptake in the body trunk and focal uptake in the extremities. The 
white blood cell count was elevated (9100/μL) and leukemia was confirmed by the detection of leukemic cells in the peripheral blood (21.5 %)
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This study had several limitations. As a retrospective 
study, there may have been a substantial selection bias 
based on the decisions of the physicians to request 18F-
FDG PET/CT. In addition, because of the small size of 
the study population, relationships between leukemia 
types and BM uptake patterns could not be fully inves-
tigated. Leukemia was not histopathologically confirmed 
at all sites with increased BM uptake because of clini-
cal and ethical considerations. Accordingly, it cannot be 
ruled out that the increased BM uptake did not always 
reflect the presence of leukemic cells. The correlation 
between the level of leukemic cell infiltration and SUV-
max was not determined, because data on the infiltration 
rate were only available for only 3 of 9 patients. However, 
taken together, the available BM examination results 
and the clinical follow-up findings strongly suggest that 
the BM uptake of 18F-FDG reflects leukemic cells activ-
ity. Further prospective studies with larger numbers of 
patients are warranted to assess the clinical utility of 18F-
FDG PET/CT in patients with leukemia.
Conclusions
Increased BM uptake of 18F-FDG can be observed in 
patients with leukemia. 18F-FDG PET/CT may be use-
ful for the non-invasive assessment of patients with sus-
pected leukemia, determination of optimal biopsy sites, 
and non-invasive response assessment. Leukemia can 
be included in the differential diagnosis of patients with 
increased BM uptake of 18F-FDG on PET/CT.
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